Log in to search using one of your social media accounts:

 

Survival in a cohort of patients with lung cancer: the role of age and gender in prognosis

ABSTRACT Objective: To determine the demographic and clinical characteristics of patients with non-small cell lung cancer (NSCLC), as well as their disease course, by age group and gender. Methods: This was a retrospective cohort study of patients diagnosed with NSCLC from 2000 to 2012 and followed until July 2015 in a tertiary referral hospital in the city of S ão Paulo, Brazil. Based on the 25th and 75th percentiles of the age distribution, patients were stratified into three age groups:
Source: Jornal Brasileiro de Pneumologia - Category: Respiratory Medicine Source Type: research

Related Links:

In this study, the effect of hyperglycemia on overall survival (OS), disease-free survival (DFS), and locoregional recurrence (LRR) was investigated in NSCLC. One stage IIIA-IIIB NSCLC patient treated with chemoradiotherapy between 2010 and 2015 was enrolled. Fasting blood glucose (FBG) levels were recorded in pre-treatment, treatment, and post-treatment periods. Median age was 54  years (51–62). Fifty-two patients had squamous cell carcinoma (SCC); 19 had adenocarcinoma. Median follow-up was 19 (11–30), median survival was 19 (13–24), and DFS was 9 (7–11) months. Diabetic patients had shorter ...
Source: Hormones and Cancer - Category: Cancer & Oncology Source Type: research
CONCLUSION: MiR-93-5p is up-regulated in NSCLC and plays an oncogenic role by inhibiting PTEN and RB1, suggesting miR-93-5p may be a novel prognostic indicator and a therapeutic target in NSCLC. PMID: 29309884 [PubMed - as supplied by publisher]
Source: Gene - Category: Genetics & Stem Cells Authors: Tags: Gene Source Type: research
In conclusion, apatinib shows some efficacy in heavily treated NSCLC and generally tolerable toxicity in non-squamous NSCLC. More solid evidence will be accessible in near future.
Source: Saudi Journal of Biological Sciences - Category: Biology Source Type: research
Date: January 1, 2018 Issue #:  1537Summary:  The immune checkpoint inhibitor pembrolizumab (Keytruda– Merck), a programmed death receptor-1 (PD-1) inhibitor, has been granted accelerated approval by the FDA for use in adults and children who have unresectable or metastatic microsatellite-instability-high (MSI-H) or mismatch-repair-deficient (dMMR) solid tumors that have progressed following trea tment, and do not have any satisfactory alternative treatment options. For metastatic colorectal cancer, the indication is limited to tumors that have progressed following combination treatment w...
Source: The Medical Letter - Category: Drugs & Pharmacology Authors: Source Type: research
Authors: Prabhu VV, Devaraj N Abstract Lung cancer is responsible for 1.6 million deaths. Approximately 80%-85% of lung cancers are of the non-small-cell variety, which includes squamous cell carcinoma, adenocarcinoma, and large-cell carcinoma. Knowing the stage of cancer progression is a requisite for determining which management approach-surgery, chemotherapy, radiotherapy, and/or immunotherapy-is optimal. Targeted therapeutic approaches with antiangiogenic monoclonal antibodies or tyrosine kinase inhibitors are one option if tumors harbor oncogene mutations. Another, newer approach is directed against cancer-spe...
Source: Journal of Environmental Pathology, Toxicology and Oncology - Category: Environmental Health Tags: J Environ Pathol Toxicol Oncol Source Type: research
Conclusions: An overrepresentation of fibrotic stroma and IL1β in the tumor sample in NSCLC is associated with 3 year mortality, a finding confirming that survival in LC partly depends on tissue characteristics other than the tumor cell.Funded by PII Oncology SEPAR/FIS 12-02040
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Lung Cancer Source Type: research
Background and Aim: Early and differential diagnosis, histological subtyping are important issues in the management of patients with lung cancer (LC). The aim of this study is to investigate the diagnostic value of a panel of serum tumor markers in newly diagnosed LC.Methods:Venous blood samples were collected from 99 patients with LC (42 adenocarcinoma, 35 squamous, and 22 small cell carcinoma) and from 30 patients with benign lung disease. Progastrin releasing peptide (PGRP), squamous cell carcinoma antigen (SCCAg), cytokeratin 19-fragments (CYFRA 21.1), human epididymis protein 4 (HE4), Chromogranin A (CgA) and neuron s...
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Lung Cancer Source Type: research
Conclusion: Nivolumab demonstrated clinically meaningful activity and satisfactory safety profile as 2nd line treatment for patients with advanced NSCLC.
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Lung Cancer Source Type: research
Introduction: Brain metastases (BM) are a common complication for patients with non-small-cell lung cancer (NSCLC) and a significant cause of morbidity and mortality. The aim of this study was to evaluate the management of BM for patients with NSCLC.Methods: This was a retrospective study including 100 patients with BM of NSCLC hospitalized in our service between January 2009 and December 2015.Results: Median age was 57 years, 94 patients were male. Ninety patients (90%) were smokers. The performans status was
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Lung Cancer Source Type: research
Conclusion A background history of smoking and male predominance was seen in the majority of the diagnoses of NSCLC in all three metropolitan hospitals with Alfred and St. Vincent’s hospitals appearing to have slightly better overall outcomes.
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Lung Cancer Source Type: research
More News: Adenocarcinoma | Brazil Health | Cancer | Cancer & Oncology | Carcinoma | Lung Cancer | Non-Small Cell Lung Cancer | Skin Cancer | Squamous Cell Carcinoma | Statistics | Study | Women